A Safety Study of SGN-CD19A for Leukemia and Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
Burkitt Lymphoma|Precursor B-cell Lymphoblastic Leukemia-Lymphoma
DRUG: SGN-CD19A
Incidence of adverse events, Through 1 month post last dose|Incidence of laboratory abnormalities, Through 1 month post last dose
Objective response according to modified response criteria for acute myeloid leukemia (Cheson 2003) or revised response criteria for malignant lymphoma (Cheson 2007), Through 1 month post last dose|Duration of response, Until disease progression or start of new anticancer treatment, an expected average of 3 months|Overall survival, Until death or study closure, an expected average of 6 months|Blood concentrations of SGN-CD19A and metabolites, Cycles 1, 2, and 4: predose, 30 minutes, and up to 2, 4, 8, 24, 72, 120, 168, and 336 hours post dose start; All other cycles: predose, 30 minutes, and 168 and 336 hours post dose start; and 1 month post last dose|Incidence of antitherapeutic antibodies, Predose in most cycles and 1 month post last dose
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).